TD Cowen lowered the firm’s price target on Charles River (CRL) to $179 from $182 and keeps a Hold rating on the shares. The firm updated its model following Q4 results and 2025 guidance. They believe they could be susceptible to further stepdowns if pharma were to undergo another round of R&D cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Cautious Outlook for Charles River Labs Amid Revenue Declines and Regulatory Concerns
- Charles River Labs Hold Rating: Balancing Strong Financial Performance with Cautious 2025 Outlook
- Charles River price target lowered to $173 from $177 at Baird
- Charles River price target lowered to $160 from $166 at Barclays
- Charles River Labs: Hold Rating Amid Uncertain FY25 Outlook Due to Biopharma Demand and DSA Challenges